COVID-19 vaccine boosters for all adults: An optimal U.s. approach?

Annals of Internal Medicine 175 (2):280-282 (2022)
  Copy   BIBTEX


By 20 October 2021, the U.S. Food and Drug Administration (FDA) had amended its Emergency Use Authorizations for immunocompetent adults who previously received the Pfizer-BioNTech, Moderna, or Johnson & Johnson COVID-19 vaccines. For the 2-dose Pfizer-BioNTech and Moderna vaccines, the FDA permitted a single booster dose for adults aged 65 years or older and adults aged 18 to 64 years at high-risk for severe COVID-19 or at high risk for occupational or institutional COVID-19 exposure. For the single-dose Johnson & Johnson vaccine, the FDA permitted a single booster dose for all adults aged 18 or older. These eligibility schemes were endorsed by the Centers for Disease Control and Prevention shortly after FDA approval.

Similar books and articles

Ethical allocation of future COVID-19 vaccines.Rohit Gupta & Stephanie R. Morain - 2021 - Journal of Medical Ethics 47 (3):137-141.
Infection-acquired versus vaccine-induced immunity against covid-19.Tsvetelina Velikova - 2021 - Central Asian Journal of Medical Hypotheses and Ethics 2 (1):29-35.


Added to PP

417 (#47,945)

6 months
111 (#38,131)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Govind Persad
University of Denver

Citations of this work

Two Kinds of Vaccine Hesitancy.Joshua Kelsall & Tom Sorell - 2024 - Social Epistemology:1-16.

Add more citations

References found in this work

No references found.

Add more references